Radiopharm Theranostics Limited (ASX:RAD) Annual Report 2026



The latest annual report of Radiopharm Theranostics Limited (RAD) was published on 30 Jun 2026. An annual report is a document that public corporations must provide annually to shareholders that describes their operations and financial conditions. Typically, an annual report will contain sections such as General corporate information, Operating and Financial highlights, Letter to shareholders from the CEO, Financial statements etc.

Key Statistics - RAD Annual Results

Amounts in AUD

Total Revenue
$1.99M
Gross Profit
$-34.34M
EBIT
$-51.51M
Net Tangible Assets
$30.64M
Net Income
$-39.67M
Capital Expenditures
-

RAD Income Statement 2026 Annual Report

As per the latest Income Statement of RAD, the Net revenue decreased by $-379.91K (-16%) compared to the previous period. The operating income in 2026 increased by - (-). The net income as per the annual report was $-39.67M which decreased by $-14.65M (-59%) compared to previous year.

Income Statement Report (2026/2025)

2026 2025
Total Revenue $1.99M $2.37M
Gross Profit $-34.34M $-34.34M
Operating Income - -
Income Before Tax - -
Net Income $-39.67M $-25.02M

Balance Sheet - RAD 2026 Annual Report

Read further: RAD Balance Sheet Detailed Analysis

The latest balance sheet from annual result of Radiopharm Theranostics Limited showed the company increased the cash on balance sheet by $0.00 (0%). The Net tangible assets of RAD on the balance sheet were at $30.64M which is $0.00 (0%) more than previous annual report. The total stockholder equity also increased by - (-) compared to previous reporting period.

Balance Sheet Statement Report (2026/2025)

2026 2025
Cash $4.14M $4.14M
Total Assets - -
Long Term Debt - -
Total Liabilities - -
Total Shareholder Equity - -
Net Tangible Assets $30.64M $30.64M

Cash Flow Statement - RAD 2026 Annual Report

The 2026 annual cash flow statement of Radiopharm Theranostics Limited showed that the net income decreased by $-14.65M (-59%) compared to previous reporting period. Also the capital expenditure of RAD increased by - (-).

As of 2026, the total cash from investing activities was - and total cash from financing activities was -.

Cash Flow Statement Report (2026/2025)

2026 2025
Net Income $-39.67M $-25.02M
Capital Expenditures - -
Dividends Paid - -
Total Cash From From Investing Activities - -
Total Cash From From Financing Activities - -

Radiopharm Theranostics Limited Annual Report History

Income Statement

Income Statement history of Radiopharm Theranostics Limited (ASX:RAD)

30 Jun 2026 30 Jun 2025 30 Jun 2024 30 Jun 2023
Total Revenue $1.99M $2.37M $203.21K $189.29K
Cost Of Revenue $0.00 $0.00 $0.00 $0.00
Gross Profit $0.00 $0.00 $0.00 $0.00
Research Development - - - -
Selling General Administrative - - - -
Non Recurring - - - -
Other Operating Expenses - - - -
Total Operating Expenses $0.00 $0.00 $0.00 $0.00
Operating Income - - - -
Total Other Income Expense Net - - - -
Ebit $0.00 $0.00 $0.00 $0.00
Interest Expense - - - -
Income Before Tax - - - -
Income Tax Expense $0.00 $0.00 $0.00 $0.00
Minority Interest - - - -
Net Income From Continuing Ops - - - -
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect Of Accounting Charges - - - -
Other Items - - - -
Net Income $-39.67M $-25.02M $-32.56M $-22.41M
Net Income Applicable To Common Shares - - - -

Balance Sheet Statement

Balance Sheet Statement history of Radiopharm Theranostics Limited (ASX:RAD)

30 Jun 2026 30 Jun 2025 30 Jun 2024 30 Jun 2023
Cash $4.14M $4.14M - -
Total Assets - - - -
Total Liab - - - -
Long Term Debt - - - -
Total Stockholder Equity - - - -
Net Tangible Assets $30.64M $30.64M - -

Cash Flow Statement

Cash Flow Statement history of Radiopharm Theranostics Limited (ASX:RAD)

30 Jun 2026 30 Jun 2025 30 Jun 2024 30 Jun 2023
Net Income $-39.67M $-25.02M - -
Capital Expenditures - - - -
Dividends Paid - - - -
Total Cashflows From Investing Activities - - - -
Total Cash From Financing Activities - - - -